KenjiM.CunnionMD

Associate Professor, Pediatrics, Eastern Virginia Medical School

Dr. Cunnion is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
601 Childrens Ln
Norfolk, VA 23507
Phone+1 757-668-7238

Fax+1 757-668-8275

Duke University HospitalFellowship, Pediatric Infectious Diseases, 1996 - 2000
Virginia Commonwealth University Health SystemResidency, Pediatrics, 1993 - 1996
Duke University School of MedicineClass of 1993

PubMed

16 citations
Complement Activation and STAT4 Expression Are Associated with Early Inflammation in Diabetic Wounds.
Kenji M. Cunnion, Neel K. Krishna, Haree K. Pallera, Angela Pineros-Fernandez, Magdielis Gregory Rivera
Plos One. 2017-01-20
74 citations
Staphylococcus aureus Clumping Factor A Binds to Complement Regulator Factor I and Increases Factor I Cleavage of C3b
Pamela S. Hair, Michael D. Ward, O. John Semmes, Timothy J. Foster, Kenji M. Cunnion
The Journal of Infectious Diseases. 2008-07-01
20 citations
Role of molecular diagnostics in the management of infectious disease emergencies.
Neel K. Krishna, Kenji M. Cunnion
The Medical Clinics of North America. 2012-11-01

$ReAlta Life Sciences Granted FDA Orphan Drug Designation and Fast Track Designation for RLS-0071 for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease$
ReAlta Life Sciences Granted FDA Orphan Drug Designation and Fast Track Designation for RLS-0071 for the Treatment of Steroid-Refractory Acute Graft-Versus-Host DiseaseAugust 19th, 2024
ReAlta Life Sciences, Inc. Doses First Patient in Phase 1b Inhaled-LPS Challenge Clinical Trial to Support Development of RLS-0071 in Severe AsthmaJune 4th, 2022
ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseFebruary 22nd, 2024
Join now to see all

Staphylococcus Aureus Binds Factor H To Moderate Complement Host DefenseNational Institute Of Allergy And Infectious Diseases2009–2010
Complement And The Clearance Of Staphylococcus AureusNational Institute Of Allergy And Infectious Diseases2002–2006
Complement And The Clearance Of Staphylococcus AureusNational Institute Of Allergy And Infectious Diseases2002